Product Description
Mechanisms of Action: nAChR Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Institute on Drug Abuse (NIDA)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Acute Pain|Chronic Pain
Phase 2: Tobacco Use Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| First Breath | N/A |
Recruiting |
Tobacco Use Disorder|Pregnancy Outcomes |
2025-07-01 |
2025-06-05 |
||
| PRE_Smoking | N/A |
Completed |
Pre-Eclampsia|Hypertension, Pregnancy-Induced|Pregnancy Outcomes |
2022-09-30 |
2024-10-24 |
||
| CANICE | N/A |
Unknown status |
Carcinogenesis|Tobacco Use Disorder |
2017-11-01 |
2024-12-19 |
Primary Endpoints|Treatments |
|
| NCT03062709 | N/A |
Completed |
Pneumonia|Asthma|Bronchiolitis|Smoking Cessation|Tobacco Use Disorder|Bronchopulmonary Dysplasia |
2017-03-30 |
2021-04-27 |
Primary Endpoints|Treatments |
|
| R01HL066307 | N/A |
Completed |
Asthma |
2008-01-01 |
2019-03-21 |
Treatments |
|
| ENtiCe | N/A |
Not yet recruiting |
Pregnancy Outcomes|Tobacco Use Disorder |
None |
2024-04-03 |
Treatments |
|
| SCUSF 1201 | P2 |
Withdrawn |
Tobacco Use Disorder |
2016-06-01 |
2019-03-19 |
Treatments |
|
| NIDA-09259-5 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
| NIDA-09259-1 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
| NIDA-09259-13 | P2 |
Completed |
Tobacco Use Disorder |
None |
2019-03-21 |
Treatments |
|
| NCT04274673 | P4 |
Unknown status |
Chronic Pain|Acute Pain |
2020-05-13 |
2022-02-02 |
Primary Endpoints|Treatments|Trial Status |